Home Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects
Article
Licensed
Unlicensed Requires Authentication

Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects

  • Miao Hu , Ya-Ling Yang , Benny S.P. Fok , Sze-Wa Chan , Tanya T.W. Chu , Emily W.M. Poon , Ophelia Q.P. Yin , Vincent H.L. Lee and Brian Tomlinson EMAIL logo
Published/Copyright: January 9, 2012
Become an author with De Gruyter Brill
Drug Metabolism and Personalized Therapy
From the journal Volume 27 Issue 1

Abstract

Background: Although flecainide is thought to be meta­bolized predominantly by cytochrome P450 (CYP) 2D6, it shows pharmacokinetic interactions with drugs, such as verapamil and digoxin, which may suggest other CYP pathways or ATP-binding cassette (ABC) transporters might be involved. This study evaluated effects of common polymorphisms in Chinese in CYP2D6, CYP3A5, CYP1A2, and ABCB1 on flecainide pharmacokinetics.

Methods: Single oral 100-mg doses of flecainide were given to 15 healthy male Chinese subjects who were genotyped for the CYP2D6*2, *5, *10, CYP3A5*3, CYP1A2*1F and ABCB1 C1236T, G2677T/A, and C3435T polymorphisms.

Results: There was no significant difference in the pharmacokinetics of flecainide among CYP2D6 (mainly involving *10) genotypes. The CYP3A5*3/*3 subjects (n=8) had a 26% higher systemic exposure (AUC0–∞) and 17% lower apparent oral clearance of flecainide than the combined group of CYP3A5*1/*1 (n=6) and CYP3A5*1/*3 (n=1) subjects (p<0.05). Subjects homozygous for CYP1A2*1F tended to have lower systemic exposure and increased clearance of flecainide compared to those with CYP1A2*1A/1F in subjects with at least one CYP2D6 variant allele.

Conclusions: The disposition of flecainide appeared to be influenced by the CYP3A5*3 and possibly the CYP1A2*1F polymorphisms, particularly in subjects with CYP2D6 variant alleles.


Corresponding author: Professor Brian Tomlinson, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Phone: +852-2632-3139, Fax: +852-2632-3139

Received: 2011-9-28
Accepted: 2011-12-1
Published Online: 2012-01-09
Published in Print: 2012-03-01

©2012 by Walter de Gruyter Berlin Boston

Downloaded on 31.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/dmdi-2011-0032/html
Scroll to top button